CL2003001545A1 - Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei - Google Patents

Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei

Info

Publication number
CL2003001545A1
CL2003001545A1 CL200301545A CL2003001545A CL2003001545A1 CL 2003001545 A1 CL2003001545 A1 CL 2003001545A1 CL 200301545 A CL200301545 A CL 200301545A CL 2003001545 A CL2003001545 A CL 2003001545A CL 2003001545 A1 CL2003001545 A1 CL 2003001545A1
Authority
CL
Chile
Prior art keywords
dismenorrea
quinolina
chromene
endometriosis
lei
Prior art date
Application number
CL200301545A
Other languages
English (en)
Spanish (es)
Inventor
Lin Van Oeveren Cornelis P Zhi
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of CL2003001545A1 publication Critical patent/CL2003001545A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL200301545A 2002-10-11 2003-08-04 Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei CL2003001545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41796802P 2002-10-11 2002-10-11

Publications (1)

Publication Number Publication Date
CL2003001545A1 true CL2003001545A1 (es) 2005-01-07

Family

ID=31994318

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200301545A CL2003001545A1 (es) 2002-10-11 2003-08-04 Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei

Country Status (12)

Country Link
US (1) US7163946B2 (enExample)
EP (1) EP1554283A1 (enExample)
JP (1) JP2006504737A (enExample)
AR (1) AR040781A1 (enExample)
AU (1) AU2003258051A1 (enExample)
CA (1) CA2501834A1 (enExample)
CL (1) CL2003001545A1 (enExample)
DE (1) DE20301728U1 (enExample)
HK (1) HK1055059A2 (enExample)
MX (1) MXPA05003801A (enExample)
TW (1) TW200413384A (enExample)
WO (1) WO2004033461A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
JP2006504736A (ja) * 2002-10-11 2006-02-09 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的プロゲステロンレセプター調節化合物としての５−（１’，１’−シクロアルキル／アルケニル）メチリデン１，２−ジヒドロ−５Ｈ−クロメノ［３，４−ｆ］キノリン
TW200410968A (en) * 2002-10-11 2004-07-01 Ligand Pharm Inc 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
JP7085056B2 (ja) * 2018-07-12 2022-06-15 イーライ リリー アンド カンパニー 選択的エストロゲン受容体分解剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635941A (en) * 1969-04-01 1972-01-18 Eastman Kodak Co Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
US3907507A (en) * 1971-04-26 1975-09-23 Heliodoro Monroy Rivera Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
CA2396738C (en) 1990-11-30 2006-08-29 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
JPH04316557A (ja) 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd ６−アリール環状アントラニル酸誘導体
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
DE69531998T2 (de) 1994-12-22 2004-07-22 Ligand Pharmaceuticals, Inc., San Diego Steroidrezeptor-modulator verbindungen und methoden
US6696459B1 (en) * 1994-12-22 2004-02-24 Ligand Pharmaceuticals Inc. Steroid receptor modulator compounds and methods
US5688808A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
ES2168650T3 (es) 1996-06-27 2002-06-16 Ligand Pharm Inc Compuestos y metodos moduladores de receptores de androgenos.
US6506766B1 (en) * 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
JP2002503665A (ja) * 1998-02-13 2002-02-05 アボット・ラボラトリーズ グルココルチコイド選択的抗炎症剤
US6380207B2 (en) * 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6093826A (en) * 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
TW200410968A (en) * 2002-10-11 2004-07-01 Ligand Pharm Inc 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
JP2006504736A (ja) * 2002-10-11 2006-02-09 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的プロゲステロンレセプター調節化合物としての５−（１’，１’−シクロアルキル／アルケニル）メチリデン１，２−ジヒドロ−５Ｈ−クロメノ［３，４−ｆ］キノリン
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen

Also Published As

Publication number Publication date
AU2003258051A1 (en) 2004-05-04
EP1554283A1 (en) 2005-07-20
JP2006504737A (ja) 2006-02-09
TW200413384A (en) 2004-08-01
AR040781A1 (es) 2005-04-20
CA2501834A1 (en) 2004-04-22
US7163946B2 (en) 2007-01-16
MXPA05003801A (es) 2005-06-08
WO2004033461A1 (en) 2004-04-22
US20040152717A1 (en) 2004-08-05
DE20301728U1 (de) 2004-03-11
HK1055059A2 (en) 2003-12-05

Similar Documents

Publication Publication Date Title
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
IS2458B (is) Indólín-2-ón afleiður, framleiðsla og notkun þeirra sem mjaltavaka (ocytocin) viðtakabindlar
BRPI0508263B8 (pt) derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
TW200621725A (en) Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
NO20034122L (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
IS2485B (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
IL154981A0 (en) Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
EE200300587A (et) Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine
DE602005016601D1 (de) 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
NO964155L (no) Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger
CL2004000449A1 (es) Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en
EA200601908A1 (ru) Контроль прорывных кровотечений при пролонгированном режиме приёма гормональных контрацептивов
ATE265497T1 (de) Hydrierte blockcopolymerzusammensetzungen und verwendungen davon
SI1441770T1 (sl) Vaginalna formulacija lidokaina za zdravljenje uterine disritmije
CL2004000553A1 (es) Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau
CL2003001544A1 (es) Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
CL2004000838A1 (es) Uso de un antagonista del receptor de aldosterona y un agente antiobesidad para preparar un medicamento util en el tratamiento de una condicion relacionada al sistema cardiovascular.
DE60105687D1 (de) Cyclohexanderivate, diese enthaltende Flüssigkristallzusammensetzungen und Flüssigkristallanzeigevorrichtungen
IL177496A0 (en) Amido-substituted hydroxy -6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
CL2003001545A1 (es) Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei